GleamWall
中文EN

GRI GRI Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1824293 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.6%
TTM EPS YoY101.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-144.6%
ROA-107.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.8%
Debt / equity0.00x
Current ratio10.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.23x
Accruals ratio24.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$6.82M$3.77M
SG&A expense$5.16M$4.47M
Operating income-$11.98M-$8.23M
Income tax$3,000$2,000
Net income-$11.96M-$8.21M
EBITDA-$11.97M-$8.23M
EPS (basic)-121.80-1,545.55
EPS (diluted)-121.80-1,545.55
Weighted avg. shares (diluted)98,1626,547
Balance sheet
Cash & equivalents$8.23M$5.03M
Current assets$8.59M$5.62M
PP&E, net$3,000$4,000
Total assets$8.67M$5.74M
Current liabilities$2.64M$1.64M
Total liabilities$2.66M$1.71M
Shareholders' equity$6.01M$4.03M
Shares outstanding497,69318,768
Cash flow statement
Operating cash flow-$10.19M-$8.61M
Capital expenditure$3,000$0
Free cash flow-$10.19M-$8.61M
Investing cash flow-$3,000$0
Financing cash flow$13.39M$11.83M
Depreciation & amortization$4,000$4,000
Stock-based compensation$793,000$148,000

Free plan shows the latest 2 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.